PIMASERTIB AND SEROUS RETINAL DETACHMENTS

Alaa AlAli; Ahmad Bushehri; Jonathan C Park; Hatem Krema; Wai-Ching Lam

doi:10.1097/ICB.0000000000000228

PIMASERTIB AND SEROUS RETINAL DETACHMENTS

Retin Cases Brief Rep. 2016 Spring;10(2):191-6. doi: 10.1097/ICB.0000000000000228.

Authors

Alaa AlAli¹, Ahmad Bushehri, Jonathan C Park, Hatem Krema, Wai-Ching Lam

Affiliation

¹ Departments of *Ophthalmology and Vision Sciences, and †Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.

Abstract

Purpose: To report a case of multifocal serous retinal detachments associated with pimasertib.

Methods: The authors report a 26-year-old patient who developed bilateral multifocal serous retinal detachments appearing 2 days after starting pimasertib (as part of a clinical trial investigating its use in low-grade metastatic ovarian cancer) and rapidly resolving 3 days after stopping it.

Conclusion: The mechanism of MEK inhibitor induced visual toxicity remains unclear. The pathophysiology of multifocal serous retinal detachments as a complication of pimasertib is still poorly understood.

Publication types

Case Reports

MeSH terms

Administration, Oral
Adult
Dose-Response Relationship, Drug
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Niacinamide / administration & dosage
Niacinamide / adverse effects
Niacinamide / analogs & derivatives*
Ovarian Neoplasms / drug therapy
Ovarian Neoplasms / secondary
Protein Kinase Inhibitors
Retina / drug effects
Retina / pathology*
Retinal Detachment / chemically induced*
Retinal Detachment / diagnosis
Tomography, Optical Coherence
Visual Acuity

Substances

N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
Protein Kinase Inhibitors
Niacinamide